InVitae Corp (NYSE:NVTA)
March 15th, 2019
With markets going up InVitae Corp finished up $0.83 Friday, a 3.54% increase, closing at $24.28. Furthermore it hit a new 52 week high of $24.48. The stock continues to trade well at 458.16% of its 52 week low of $4.35.
Analysis results from 6 analysts points to the possibility that InVitae Corp might go down somewhat (-10.26%), while Finbox has calculated (with high uncertainty) a fair value price of $21.02.
The market sectors were mixed Friday with a majority of the sectors trending up. Information Technology saw the biggest increase of the day (1.22%), while Real Estate saw the biggest drop (-0.38%). Information Technology has seen the biggest year-to-date gain at 16.35%.
Real Estate and Industrials both saw turn arounds from their five day positive performance, Real Estate with a drop of -0.38%.
- Information Technology went up with a 1.22% change.
- Consumer Discretionary went up with a 0.71% change.
- Financials went up with a 0.64% change.
- Consumer Staples went up with a 0.50% change.
- Healthcare went up with a 0.49% change.
- Utilities went up with a 0.47% change.
- Materials went up with a 0.20% change.
- Communication Services went up with a 0.01% change.
- Energy went down with a -0.08% change.
- Industrials went down with a -0.25% change.
- Real Estate went down with a -0.38% change.
InVitae Corp Info
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company’s tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.